BridgeBio Pharma (BBIO) Q3 2025 Earnings
How Did BBIO Stock React to Q3 2025 Earnings?
S&P 500 over the same 30 days: +0.25%.
Did BBIO Beat Earnings? Q3 2025 Results
No. BridgeBio Pharma reported Q3 2025 earnings of $-0.95 a share on Oct 29, 2025, missing the $-0.78 consensus estimate by 22.3%. Revenue was $120.7M against a $105.7M estimate.
BridgeBio Pharma delivered a mixed Q3 2025 report, posting revenue that cleared Wall Street's bar while earnings fell short, as the company's explosive Attruby commercial launch collided with the heavy costs of building a multi-product genetic medicine franchise. Revenue surged to $120.70 million, a staggering 4,318% jump year-over-year and well above the $105.67 million consensus, driven almost entirely by $108.11 million in U.S. net product sales of Attruby for ATTR-CM, a drug that generated zero revenue in the year-ago period. On the bottom line, however, BridgeBio missed, reporting a loss of $0.95 per share against the $0.78 consensus estimate, a 22.31% shortfall, as SG&A expenses climbed $68.80 million to fund the launch and noncash interest charges on a new royalty monetization deal added $36.41 million in costs. The pipeline simultaneously delivered registrational wins, with BBP-418 and encaleret both meeting Phase 3 primary endpoints; BridgeBio plans NDA filings for both programs in the first half of 2026, a pipeline cadence that <a href="https://247wallst.com/investing/2025/10/27/biomarin-up-after-q3-earnings-heres-everything-you-need-to-know/">echoes momentum seen across rare disease peers</a> this earnings season.
- Strong Attruby commercial launch with 5,259 unique patient prescriptions by 1,355 unique prescribers since FDA approval in November 2024
- Accelerating growth in treatment-naïve patient segment
- Attruby clinical differentiation with JACC publication showing cardiovascular outcome benefits within first month of treatment
- 49% hazard reduction in cardiovascular mortality or recurrent cardiovascular-related hospitalizations at Month 30 versus placebo
- Royalty revenue from BEYONTTRA sales in EU and Japan
“Attruby's strong commercial performance continues to validate our model, delivering a potential best-in-class medicine to patients who were historically overlooked and building meaningful momentum across all market segments. We are now seeing that same success echoed in our pipeline with home-run data in both ADH1 and LGMD2I/R9, and we continue to advance one of the broadest and fastest-moving portfolios in genetic medicine.”
BridgeBio Pharma CEO, on the earnings call
What Was BridgeBio Pharma's Outlook in Q3 2025?
BridgeBio intends to file NDAs with the FDA for both BBP-418 (LGMD2I/R9) and encaleret (ADH1) in the first half of 2026, and plans to submit a Marketing Authorization Application to the EMA for encaleret. Topline results from PROPEL 3 for infigratinib in achondroplasia are expected in early 2026. The company plans to initiate Phase 3 studies of encaleret in chronic hypoparathyroidism and pediatric ADH1 in 2026, begin clinical trials of BBP-418 in pediatric LGMD2I/R9 and in LGMD2M/2U, and expects Phase 2 data from ACCEL 2/3 in hypochondroplasia in the second half of 2026. The company stated it is well capitalized with $645.9 million in cash, cash equivalents and marketable securities to commercialize Attruby and advance its late-stage pipeline.
BBIO YoY Financials
| Metric | Q3 2025 | Q3 2024 | Year over year |
|---|---|---|---|
| Revenue | $120.7M | $2.7M | +4,318.0% |
| Gross Profit | $114.1M | $2.1M | +5,248.5% |
| Operating Income | −$145.2M | −$116.8M | +24.3% |
| Net Income | −$182.7M | −$209.5M | −12.8% |
BBIO Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.